Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.
|Videos|March 18, 2014
Interrupting the FGFR Signaling Pathway in Pancreatic Cancer
Author(s)Wen Wee Ma, MBBS
Wen Wee Ma, MBBS, associate professor of oncology, Department of Medicine, Roswell Park Cancer Institute, discusses interrupting the FGFR signaling pathway in pancreatic cancer.
Advertisement
Clinical Pearls
Wen Wee Ma, MBBS, associate professor of oncology, Department of Medicine, Roswell Park Cancer Institute, discusses interrupting the FGFR signaling pathway in pancreatic cancer.
- The recent MPACT trial represents a major milestone in improving the survival of patients with stage IV pancreatic cancer
- The microenvironment (consisting of white blood cells, macrophages, collagens, connective tissues, and fibroblasts) in pancreatic cancer plays a major role in treatment resistance
- The fibroblast growth factor receptor (FGFR) signaling pathway is active in cancer cells in promoting proliferation, growth, and blood vessel formation
- Interrupting this pathway can cause cancer cells to undergo apoptosis
- A clinical trial is underway looking at dovitinib and gemcitabine-based chemotherapy for patients with advanced or metastatic pancreatic cancer
Advertisement
Related to this article
Broad oncology bundles falter; experts push smaller surgery/radiation episodes, better navigation, and AI analytics to improve value-based care.
In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
New analysis tracks life-years gained from blood cancer therapies, revealing breakthrough inflection points, stubborn AML gaps, and inequities in access.
For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Denosumab Biosimilar Approved For Existing Oncology Indications
2
Giredestrant Plus Everolimus Improves PFS in ER+ Advanced Breast Cancer
3
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
4
New Drug Application Filed for Savolitinib/Osimertinib in MET+ NSCLC
5